Klotho Neurosciences Acquires Turn Biotechnologies' Assets for Longevity Therapeutics

Klotho Neurosciences has signed a letter of intent to acquire assets from Turn Biotechnologies, including the Epigenetic Reprogramming of Age (ERA) platform and the eTurna RNA delivery system. The deal is contingent upon due diligence and could be worth up to $300m, including a South Korean pharmaceutical company partnership. Klotho plans to rebrand and welcome key Turn Biotechnologies personnel after the transaction is finalized. The acquisition aims to expand Klotho's focus beyond the Klotho gene to a system of cellular rejuvenation.

Klotho Neurosciences (NASDAQ: KLTO) has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, marking a significant strategic move for the company. The deal includes Turn's ERA (Epigenetic Reprogramming of Age) platform and the eTurna RNA delivery system, along with a potential out-licensing and co-development partnership worth up to $300 million with a South Korean pharmaceutical company Klotho Neurosciences to acquire select assets from Turn Biotechnologies^[1].

The acquisition aims to expand Klotho's focus beyond its original anti-aging Klotho gene research to include cellular rejuvenation technologies. The ERA platform, developed at Stanford University, utilizes six RNA molecules, including Yamanaka factors, to reprogram cells and restore tissue function. The eTurna RNA delivery system is designed to enhance the delivery of RNA-based therapies Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership^[2].

Klotho plans to rebrand and integrate key personnel from Turn Biotechnologies following the transaction's completion. The acquisition remains subject to due diligence, execution of a definitive agreement, and customary closing conditions Klotho Neurosciences signs LOI to acquire Turn Bio assets^[3].

While the aging demographic trend is compelling, with global healthcare costs expected to exceed $47 trillion by 2030, the longevity therapeutics space remains early-stage with significant regulatory and commercial uncertainties. The transaction's strategic rationale is clear, but its ultimate value will depend on successful integration and clinical advancement of the combined technology platforms Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership^[2].